-+ 0.00%
-+ 0.00%
-+ 0.00%

Orion Launches Mid-stage Study for Cancer Drug Therapy

MT Newswires·01/08/2026 05:47:20
Listen to the news
05:47 AM EST, 01/08/2026 (MT Newswires) -- Orion (ORNAV.HE) launched its phase 2 trial to evaluate its cancer treatment drug, ODM-212, in patients with malignant pleural mesothelioma and epithelioid hemangioendothelioma, or other tumors. The multicenter, open-label Teades study will focus on the drug's safety, dose, tolerability, and efficacy, on 300 participants in US and European oncology centers, according to a Thursday release. The pharmaceutical company added that it will also review ODM-212's effect on patients' overall response rate, as well as progression-free and overall survival.